Aldeyra reports reproxalap improves dry eye disease signs, symptoms
Reproxalap 0.25% ophthalmic solution achieved primary and secondary endpoints in a trial investigating treatment ofdry eye disease, Aldeyra Therapeutics announced in a press release.
In a double-masked, sequence-randomized, vehicle-controlled crossover clinical trial, a single-day dosing of reproxalap demonstrated statistically significant improvement in ocular redness in a dry eye chamber (P= .0004) and in tear production as measured by Schirmer test (P= .0005). Results were observed as soon as 10 minutes after administration, the release stated.
Secondary endpoint measurements of dryness (P= .0068), discomfort (P= .0001), grittiness (P= .0001), stinging (P= .0001), burning (P= .0001) and itching (P= .0003) also were significantly improved.
“Withanother set of positive clinical resultsshowing improvement in both the signs and symptoms of dry eye disease, I believe that reproxalap is an eagerly anticipated advancement for our patients suffering from dry eye disease, because available therapies are often inadequate,”John P. Berdahl, MD,a specialist at Vance Thompson Vision and professor of ophthalmology at the Sanford School of Medicine in South Dakota, saidin the release.
Data from the trial will be used as part of a dry eye disease new drug application for reproxalap, the company stated.